Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
-
最新报道：Novo Nordisk's Ozempic and Wegovy, blockbuster diabetes and weight-loss drugs, saw sales growth slow in Q1 2024 despite still rising 22% year-over-year to $9.38 billion. The Danish pharma giant now faces supply constraints and manufacturing challenges as demand outstrips production capacity. While maintaining its 2024 outlook, Novo acknowledged the need to "significantly increase" supply to meet overwhelming global demand. The company's stock dipped slightly despite strong earnings, as investors weigh whether the GLP-1 drug hype cycle has peaked amid intensifying competition from Eli Lilly's rival treatments. Novo remains Europe's most valuable company with a $570 billion market cap.
下一篇
Bitcoin News Today: Figma Files for $1.2 Billion IPO as It Discloses $70M Bitcoin and $30M Ethereum Holdings via ETFs
- Figma has filed for a $1.2 billion IPO, revealing it holds $70 million in Bitcoin and $30 ...
24小时热点
热点专题
417812